Drug Trial Radar · NCT03390387
Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)
Last checked: Nov 19, 2026Latest source record: Feb 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
4,000
Planned (sponsor's estimate)
Start
Nov 2015
Primary completion
Nov 2020
Study completion Nov 2025
Sponsor
- Lead sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 4, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 year, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
QUESTIONS AND OBJECTIVES OF ALL-MB 2015 STUDY 1. Will the new risk group stratification (especially of T-ALL) to improve overall and event-free survival? 2. Will the new protocol is effective and feasible in patients older than 15 years, and especially in young adults? 3. Whether the intermittent dexamethasone administration in induction will result in a decrease in toxicity and mortality without loss of efficacy? 4. Whether the methylprednisolone administration as basic glucocorticoids during induction, consolidation and maintenance therapy will lead to decrease of severe infections and early mortality rate, improve survival and therapy compliance in adolescents and young adults with B-precursor ALL? 5. Whether the administration of Bortezomib in patients with B-precursor ALL with initial WBC≥100,000/µl will improve treatment outcome? 6. Whether the administration of Idarubicin instead Daunorubicin in low-risk T-ALL patients and two-phase induction in intermediate-risk T-ALL patients will reduce relapse rate and improve survival?
Conditions
- Childhood Acute Lymphoblastic Leukemia
Interventions
Dexamethasone continuousDrug
6 mg/m2, per os, in two divided doses per day q12 hours. 1-28 day (dose in the first few days is depending on the total tumor mass). From day 29 the dose of dexamethasone is reducing: days 29-31 - 3 mg/m2, days 32-34 - 1.5 mg/m2, days 35-36 - 0.75 mg/m2; then dexamethasone is discontinued completely.
Dexamethasone intermittentDrug
6 mg/m2, per os, in two divided doses per day q12 hours. Days: 1-14 (dose in the first few days is depending on the total tumor mass) and 22-28; days 15-21 - pause. From day 29 the dose of dexamethasone is reducing: days 29-30 - 3 mg/m2, days 31-32 - 1.5 mg/m2, then dexamethasone is discontinued completely.
DexamethasoneDrug
Induction: 6 mg/m2, per os, in two divided doses per day q12 hours. 1-28 day (dose in the first few days is depending on the total tumor mass). From day 29 the dose of dexamethasone is reducing: days 29-31 - 3 mg/m2, days 32-34 - 1.5 mg/m2, days 35-36 - 0.75 mg/m2; then dexamethasone is discontinued completely. Consolidation: 6 mg/m2 per os, in two divided doses per day q12 hours. Weeks 13-14 (days 85-98), weeks 21-22 (days 141-154), weeks 29-30 (days 197-210), weeks 37-38 (days 253-260), weeks 45-46 (days 309-316), weeks 53-54 (days 365-372). Maintenance therapy: 6 mg/m2, per os, in two divided doses per day q12 hours, for 10 days followed by quick discontinuation during 3 days. Weeks 61-62, 69-70, 77-78, 85-86, 93-94.
MethylprednisoloneDrug
Induction: 60 mg/m2, per os, in two divided doses per day q12 hours. 1-28 day (dose in the first few days is depending on the total tumor mass). From day 29 the dose of dexamethasone is reducing: days 29-31 - 30 mg/m2, days 32-34 - 15 mg/m2, days 35-36 - 8 mg/m2; then methylprednisolone is discontinued completely. Consolidation: 60 mg/m2 per os, in two divided doses per day q12 hours. Weeks 13-14 (days 85-98), weeks 21-22 (days 141-154), weeks 29-30 (days 197-210), weeks 37-38 (days 253-260), weeks 45-46 (days 309-316), weeks 53-54 (days 365-372). Maintenance therapy: 60 mg/m2, per os, in two divided doses per day q12 hours, for 10 days followed by quick discontinuation during 3 days. Weeks 61-62, 69-70, 77-78, 85-86, 93-94.
DaunorubicinDrug
Induction: 45 mg/m2, intravenously, for 6 hours on days 8 and 22. Consolidation: 30 mg/m2, intravenously, for 6 hours on days 44, 65 (consolidation S1); 107, 121 (consolidation S2); and 163 (consolidation S3).
IdarubicinDrug
Induction: 10 mg/m2, intravenously, for 6 hours on days 8 and 22. Consolidation: 8 mg/m2, intravenously, for 6 hours on days 44, 65 (consolidation S1); 107, 121 (consolidation S2); and 163 (consolidation S3).
BortezomibDrug
1.3 mg/м2, intravenously, bolus injection. Days 85, 89, 92, 96 (consolidation S1); 141, 145, 148, 152 (consolidation S2) and 197, 201, 204, 208 (consolidation S3).
Second phase of inductionDrug
Cyclophosphamide (1,000 mg/m2, intravenously, for 1 hour - days 43 and 71); Cytarabine (75 mg/m2/day, intravenously, bolus injection. Four blocks of 4 days each, days 46-48, 52-55, 59-62, and 66-69); 6-mercaptopurine (60 mg/m2/day, per os, days 43-71); Triple intrathecal therapy (days 52 and 66)
Standard induction therapyDrug
Dexamethasone (6 mg/m2, p/o; 1-29 days); Daunorubicin (45 mg/m2, i.v.; day 8 and 22); Vincristine (1.5 mg/m2, i.v.; days 8, 15, 22, 29 and 36); Triple intrathecal therapy (Methotrexate/Cytarabine/Prednisone; days 0/1, 8, 15, 22, 29 and 36)
Standard consolidation therapyDrug
Consolidation consists of 3 phases: S1, S2 and S3. Each phase is a 6-week therapy with 6-mercaptopurine (50 mg/m2 per day, daily, orally), methotrexate (30 мг/м2, i.m., weekly) and L-asparaginase (10 000 U/m2, i.m., weekly), followed by 2 weeks of re-induction with Vincristine (1.5 mg/m2, i.v., days 1 and 8 of reinduction) plus Dexamethasone (6 mg/m2, p/o, daily, for 10 days followed by quick discontinuation during 3 days). Daunorubicin (30 mg/м2, i.v., N2 during S1, N2 during S2 and N1 during S3). Triple intrathecal therapy (Methotrexate/Cytarabine/Prednisone) N12 (4 injections per each phase)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free survivalTime frame: 3 years, 5 years and 10 years after study start
- Overall survivalTime frame: 3 years, 5 years and 10 years after study start
- Cumulative incidence of relapseTime frame: 3 years, 5 years and 10 years after study start
Locations
58 sites in 5 countries. Site status is shown where the registry gives one.
prof. R.O.Eolyan Hematology Center
Yerevan, Armenia · Completed
Republican Research and Practical Center of Radiation Medicine and Human Ecology
Homyel, Belarus · Recruiting
Republic Research and Practical Center of Pediatric Oncology, Hematology and Immunology
Minsk, Belarus · Recruiting
Mogilev Regional Children's Hospital
Mogilev, Belarus · Recruiting
National Oncology and Hematology Center, Ministry of Health of the Kyrgyz Republic
Bishkek, Kyrgyzstan · Completed
Arkhangelsk Regional Clinical Children's Hospital
Arkhangelsk, Russia · Recruiting
Regional Clinical Children's Hospital
Astrakhan, Russia · Recruiting
Altay Regional Clinical Children's Hospital
Barnaul, Russia · Recruiting
Amur Regional Clinical Children's Hospital
Blagoveshchensk, Russia · Recruiting
Bryansk Regional Children's Hospital
Bryansk, Russia · Recruiting
Chelyabinsk Regional Clinical Children's Hospital
Chelyabinsk, Russia · Recruiting
Transbaikal Regional Oncology Dispensary
Chita, Russia · Recruiting
Irkutsk Regional Children Clinical Hospital
Irkutsk, Russia · Recruiting
Ivanovo Regional Clinical Hospital
Ivanovo, Russia · Recruiting
Republic Clinical Children's Hospital
Izhevsk, Russia · Recruiting
Regional Clinical Children's Hospital
Khabarovsk, Russia · Recruiting
Kirov Research Institute of Hematology and Blood Transfusion
Kirov, Russia · Recruiting
Regional Clinical Children's Hospital
Krasnodar, Russia · Recruiting
Krasnoyarsk Territorial Clinical Children's Hospital
Krasnoyarsk, Russia · Recruiting
Kurgan Regional Clinical Children's Hospital
Kurgan, Russia · Recruiting
Regional Clinical Children's Hospital
Kursk, Russia · Recruiting
Regional Children's Hospital
Lipetsk, Russia · Recruiting
Republic Children's Clinical Hospital
Makhachkala, Russia · Recruiting
Morozov Children's Municipal Clinical Hospital
Moscow, Russia · Recruiting
Research Institute of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev
Moscow, Russia · Recruiting
Russian Children's Clinical Hospital
Moscow, Russia · Recruiting
Murmansk Clinical Children's Hospital
Murmansk, Russia · Recruiting
Republic Clinical Children's Hospital
Nal'chik, Russia · Recruiting
Nizhnevartovsk Regional Clinical Children's Hospital
Nizhnevartovsk, Russia · Recruiting
Regional Clinical Children's Hospital
Nizhny Novgorod, Russia · Recruiting
Novokuznetsk Municipal Clinical Children's Hospital N4
Novokuznetsk, Russia · Recruiting
Novosibirsk Central District Clinical Hospital
Novosibirsk, Russia · Recruiting
Orenburg Regional Clinical Oncology Dispensary
Orenburg, Russia · Recruiting
Regional Clinical Children's Hospital
Oryol, Russia · Recruiting
Perm Territorial Clinical Children's Hospital
Perm, Russia · Recruiting
Regional Clinical Children's Hospital
Rostov-on-Don, Russia · Recruiting
Rostov Research Institute of Oncology
Rostov-on-Don, Russia · Recruiting
N. Dmitrieva Ryazan Regional Clinical Children's Hospital
Ryazan, Russia · Recruiting
Almazov National Medical Research Center
Saint Petersburg, Russia · Recruiting
Children's Municipal Hospital N1
Saint Petersburg, Russia · Recruiting
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.